Skip to main content

Structural Bioinformatics Uses Sequence Data to Generate Lead Molecules


SAN DIEGO, Calif.--Applying its proprietary protein-modeling technology to gene sequence data, Structural Bioinformatics here has developed a number of small-molecule nonpeptide lead molecules in multiple chemical classes that are active against the EPO receptor, the company announced recently. To find leads for a variety of structure-based drug design projects, Structural uses an analysis of target sites on a protein structure together with virtual screening. When no 3-D protein structure is available, analyses are performed on a high-quality protein model based in part on related protein structures and augmented with proprietary loop modeling and other refinements.

Edward Maggio, Structural's CEO, called the new development "another validation of our proprietary protein-modeling approach to drug design that permits rapid generation of novel leads from gene sequence for which no protein crystal structures are available."

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.